WO2023227746A3 - Signature moléculaire de lentigo actinique associée à la gestion de vésicules - Google Patents

Signature moléculaire de lentigo actinique associée à la gestion de vésicules Download PDF

Info

Publication number
WO2023227746A3
WO2023227746A3 PCT/EP2023/064124 EP2023064124W WO2023227746A3 WO 2023227746 A3 WO2023227746 A3 WO 2023227746A3 EP 2023064124 W EP2023064124 W EP 2023064124W WO 2023227746 A3 WO2023227746 A3 WO 2023227746A3
Authority
WO
WIPO (PCT)
Prior art keywords
management
skin
vesicle
pigmentary
genes
Prior art date
Application number
PCT/EP2023/064124
Other languages
English (en)
Other versions
WO2023227746A2 (fr
Inventor
Emilie WARRICK
Françoise Bernerd
Charlène GAYRARD
Christine Duval
Original Assignee
L'oreal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by L'oreal filed Critical L'oreal
Publication of WO2023227746A2 publication Critical patent/WO2023227746A2/fr
Publication of WO2023227746A3 publication Critical patent/WO2023227746A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/35—Ketones, e.g. benzophenone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
    • A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/148—Screening for cosmetic compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La présente invention concerne une méthode de caractérisation d'une tache pigmentaire de la peau apparente ou suspecté chez un être humain, comprenant la mesure des niveaux d'expression puis la comparaison des niveaux d'expression mesurés, dans des échantillons de peau provenant de ladite tache et provenant de la peau non lésée adjacente, d'au moins un gène impliqué dans la gestion de vésicules, de préférence des mélanosomes, choisi dans la liste constituée des gènes JAKMIP2, ARC, KIF21A, SLITRK6, NRN1, SCIN, SYNPO2, TNNT1, SNTB1, ARHGAP29, RAB3IP, RHOBTB3, RASIP1, ASGR1, CHMP4C, SVIP, LRMP, NAV3 et PCLO. L'invention concerne également des méthodes d'évaluation de l'efficacité d'un traitement des taches pigmentaires, des méthodes cosmétiques de traitement des taches pigmentaires, ainsi que divers modulateurs desdits gènes et leur utilisation.
PCT/EP2023/064124 2022-05-25 2023-05-25 Signature moléculaire de lentigo actinique associée à la gestion de vésicules WO2023227746A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR2205044A FR3135992A1 (fr) 2022-05-25 2022-05-25 Signature moléculaire du lentigo actinique associée à la gestion des vésicules
FRFR2205044 2022-05-25

Publications (2)

Publication Number Publication Date
WO2023227746A2 WO2023227746A2 (fr) 2023-11-30
WO2023227746A3 true WO2023227746A3 (fr) 2024-01-04

Family

ID=85222013

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2023/064124 WO2023227746A2 (fr) 2022-05-25 2023-05-25 Signature moléculaire de lentigo actinique associée à la gestion de vésicules

Country Status (2)

Country Link
FR (1) FR3135992A1 (fr)
WO (1) WO2023227746A2 (fr)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009140550A2 (fr) * 2008-05-14 2009-11-19 Dermtech International Diagnostic de mélanome et de lentigo solaire par analyse d'acides nucléiques
WO2012013776A2 (fr) * 2010-07-30 2012-02-02 Nestec S.A. Utilisation de grains de café vert pour réguler des troubles de la pigmentation de la peau
US20120244131A1 (en) * 2011-02-04 2012-09-27 Cellectis Sa Method for modulating the efficiency of double-strand break-induced mutagenesis
FR2974370A1 (fr) * 2011-04-22 2012-10-26 Oreal Signature moleculaire des taches pigmentaires cutanees, associee a la voie de signalisation tgf-beta - smad
US20150166646A1 (en) * 2012-06-15 2015-06-18 The Wistar Institute Of Anatomy And Biology Methods and Compositions for Treating or Diagnosing Melanoma
US20200348313A1 (en) * 2019-03-19 2020-11-05 Incyte Corporation Biomarkers for vitiligo

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR332E (fr) 1902-01-04 1902-12-11 Ostwald Wilhelm Procédé de fabrication de l'acide nitrique
FR2974372B1 (fr) 2011-04-22 2016-09-02 Oreal Signature moleculaire des taches pigmentaires cutanees, associee au remodelage de la matrice extracellulaire
FR2974371B1 (fr) 2011-04-22 2016-10-28 Oreal Signature moleculaire des taches pigmentaires cutanees, associee a la famille des proteoglycanes et glycoproteines extracellulaires
FR2974373B1 (fr) 2011-04-22 2016-09-02 Oreal Signature moleculaire des taches pigmentaires cutanees, associee a la matrice extracellulaire

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009140550A2 (fr) * 2008-05-14 2009-11-19 Dermtech International Diagnostic de mélanome et de lentigo solaire par analyse d'acides nucléiques
WO2012013776A2 (fr) * 2010-07-30 2012-02-02 Nestec S.A. Utilisation de grains de café vert pour réguler des troubles de la pigmentation de la peau
US20120244131A1 (en) * 2011-02-04 2012-09-27 Cellectis Sa Method for modulating the efficiency of double-strand break-induced mutagenesis
FR2974370A1 (fr) * 2011-04-22 2012-10-26 Oreal Signature moleculaire des taches pigmentaires cutanees, associee a la voie de signalisation tgf-beta - smad
US20150166646A1 (en) * 2012-06-15 2015-06-18 The Wistar Institute Of Anatomy And Biology Methods and Compositions for Treating or Diagnosing Melanoma
US20200348313A1 (en) * 2019-03-19 2020-11-05 Incyte Corporation Biomarkers for vitiligo

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
ESPINOSA ERIC J. ET AL: "RhoBTB3: A Rho GTPase-Family ATPase Required for Endosome to Golgi Transport", CELL, vol. 137, no. 5, 29 May 2010 (2010-05-29), Amsterdam NL, pages 938 - 948, XP093105994, ISSN: 0092-8674, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2801561/pdf/nihms108740.pdf> DOI: 10.1016/j.cell.2009.03.043 *
GUO WEIHONG ET AL: "Promotion of Cell Proliferation through Inhibition of Cell Autophagy Signalling Pathway by Rab3IP is Restrained by MicroRNA-532-3p in Gastric Cancer", JOURNAL OF CANCER, vol. 9, no. 23, 1 January 2018 (2018-01-01), AU, pages 4363 - 4373, XP093105955, ISSN: 1837-9664, Retrieved from the Internet <URL:https://www.jcancer.org/v09p4363.pdf> DOI: 10.7150/jca.27533 *
HUAN LIU ET AL: "Exome sequencing provides additional evidence for the involvement of ARHGAP29 in Mendelian orofacial clefting and extends the phenotypic spectrum to isolated cleft palate", BIRTH DEFECTS RESEARCH, JOHN WILEY & SONS, INC, HOBOKEN, USA, vol. 109, no. 1, 23 January 2017 (2017-01-23), pages 27 - 37, XP072279705, ISSN: 2472-1727, DOI: 10.1002/BDRA.23596 *
ORTONNE J-P: "Management of actinic lentigo and melasma: ECLAIR international study. Profile of patients, conditions and efficiency of Iklen(R) Rucinol treatment", NOUVELLES DERMATOLOGIQUES, STRASBOURG, FR, vol. 26, no. 8, 1 January 2007 (2007-01-01), pages 499 - 504, XP009093664, ISSN: 0752-5370 *
ROSSI A.B.: "Clinical and instrumental efficacy of a dermocosmetic with Uniwhite peptide, niacinamide, vitC and hyaluronic acid on reducing actinic lentigo and improving photoaging", JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, vol. 74, no. 5, 31 May 2016 (2016-05-31), XP029517864, ISSN: 0190-9622, DOI: 10.1016/J.JAAD.2016.02.911 *
WARRICK E ET AL: "Morphological and molecular characterization of actinic lentigos reveals alterations of the dermal extracellular matrix", BRITISH JOURNAL OF DERMATOLOGY, JOHN WILEY, HOBOKEN, USA, vol. 177, no. 6, 16 November 2017 (2017-11-16), pages 1619 - 1632, XP071054051, ISSN: 0007-0963, DOI: 10.1111/BJD.15697 *
WARRICK E ET AL: "Supplementary information 1 for "Morphological and molecular characterization of actinic lentigos reveals alterations of the dermal extracellular matrix"", BRITISH JOURNAL OF DERMATOLOGY, 1 June 2017 (2017-06-01), pages 1 - 12, XP093037680, Retrieved from the Internet <URL:https://onlinelibrary.wiley.com/action/downloadSupplement?doi=10.1111%2Fbjd.15697&file=bjd15697-sup-0001-Supinfo1.pdf> [retrieved on 20230405] *
WARRICK E ET AL: "Supplementary Material 2 for "Morphological and molecular characterization of actinic lentigos reveals alterations of the dermal extracellular matrix"", BRITISH JOURNAL OF DERMATOLOGY, 1 June 2017 (2017-06-01), pages 1 - 3, XP093037681, Retrieved from the Internet <URL:https://onlinelibrary.wiley.com/action/downloadSupplement?doi=10.1111%2Fbjd.15697&file=bjd15697-sup-0002-Supinfo2.pdf> [retrieved on 20230405] *
WU ZHIQIANG ET AL: "Identification of Glutaminyl Cyclase isoenzyme isoQC as a regulator of SIRP[alpha]-CD47 axis", CELL RESEARCH, SPRINGER SINGAPORE, SINGAPORE, vol. 29, no. 6, 14 May 2019 (2019-05-14), pages 502 - 505, XP036854726, ISSN: 1001-0602, [retrieved on 20190514], DOI: 10.1038/S41422-019-0177-0 *

Also Published As

Publication number Publication date
WO2023227746A2 (fr) 2023-11-30
FR3135992A1 (fr) 2023-12-01

Similar Documents

Publication Publication Date Title
Sabarinathan et al. Nucleotide excision repair is impaired by binding of transcription factors to DNA
Ben-Hamo et al. MicroRNA regulation of molecular pathways as a generic mechanism and as a core disease phenotype
Ozawa et al. Most human non-GCIMP glioblastoma subtypes evolve from a common proneural-like precursor glioma
Staub et al. Epigenetic silencing of HSulf-1 in ovarian cancer: implications in chemoresistance
Małachowska et al. Circulating microRNAs as biomarkers of radiation exposure: A systematic review and meta-analysis
Li et al. Transcriptome analysis reveals distinct patterns of long noncoding RNAs in heart and plasma of mice with heart failure
Ott et al. MicroRNAs differentially expressed in postnatal aortic development downregulate elastin via 3′ UTR and coding-sequence binding sites
Hanna et al. Quantitative analysis of microRNAs in tissue microarrays by in situ hybridization
Zhang et al. Highly expressed lncRNA CCND2-AS1 promotes glioma cell proliferation through Wnt/β-catenin signaling
Liu et al. Loss of androgen-regulated microRNA 1 activates SRC and promotes prostate cancer bone metastasis
Cai et al. LncRNA SNHG6 acts as a prognostic factor to regulate cell proliferation in glioma through targeting p21
Bartys et al. The regulation properties of RNA secondary structure in alternative splicing
Goering et al. LABRAT reveals association of alternative polyadenylation with transcript localization, RNA binding protein expression, transcription speed, and cancer survival
Chung et al. Computational analysis concerning the impact of DNA accessibility on CRISPR-Cas9 cleavage efficiency
Yamada et al. UV irradiation‐induced DNA hypomethylation around WNT1 gene: Implications for solar lentigines
Cortés-López et al. High-throughput mutagenesis identifies mutations and RNA-binding proteins controlling CD19 splicing and CART-19 therapy resistance
Rahm et al. HDAC2-dependent remodeling of KCa2. 2 (KCNN2) and KCa2. 3 (KCNN3) K+ channels in atrial fibrillation with concomitant heart failure
Choh et al. Does ligation of the thoracic duct during oesophagectomy reduce the incidence of post-operative chylothorax?
Han et al. Epigenetic silencing of the Wnt antagonist APCDD1 by promoter DNA hyper-methylation contributes to osteosarcoma cell invasion and metastasis
Anbar et al. The hair follicle melanocytes in vitiligo in relation to disease duration
WO2023227746A3 (fr) Signature moléculaire de lentigo actinique associée à la gestion de vésicules
WO2012172221A3 (fr) Signature moléculaire des taches pigmentaires cutanées, associée à l&#39;organisation de la matrice extracellulaire
McCann et al. APOBEC3B regulates R-loops and promotes transcription-associated mutagenesis in cancer
Pecrix et al. DNA demethylation and hypermethylation are both required for late nodule development in Medicago
Gravas Hot topics in the clinical practice guidelines for treatment of Male lower urinary tract symptoms due to benign prostatic obstruction

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23729712

Country of ref document: EP

Kind code of ref document: A2